Table 2.
Antimicrobials used for patients infected and not infected with extended-spectrum β-lactamase (ESBL)-producing E. coli
| ESBL (+) n=14 (%) |
ESBL (-) n=14 (%) |
P | |
|---|---|---|---|
| Penicillins | 4 (28.6) | 3 (21.4) | N.S. |
| 1st-generation cephalosporins | 6 (42.9) | 4 (28.6) | N.S. |
| 2nd-generation cephalosporins | 3 (21.4) | 3 (21.4) | N.S. |
| 3rd-generation cephalosporins | 2 (14.3) | 3 (21.4) | N.S. |
| 4th-generation cephalosporins | 8 (57.1) | 4 (28.6) | N.S. |
| 1st-4th generation cephalosporins | 10 (71.5) | 10 (71.5) | N.S. |
| Lyncosamide | 2 (14.3) | 1 (7.1) | N.S. |
| Carbapenems | 2 (14.3) | 1 (7.1) | N.S. |
| Tetracycline | 1 (7.1) | 0 (0) | N.S. |
| Aminoglycosides | 2 (14.3) | 0 (0) | N.S. |
| Fluoroquinolones | 1 (7.1) | 1 (7.1) | N.S. |
| Anti-MRSA | 1 (7.1) | 0 (0) | N.S. |
| Number of antimicrobials used | 12 (85.7) | 12 (85.7) | N.S. |
| Days of antimicrobial use (mean ± SD) | 12.8 ± 13.5 | 7.6 ± 4.7 | *N.S. |
| Number of patients treated with two or more antimicrobials | 3 (21.4) | 1 (7.1) | N.S. |
| Maximum number of days of use of same antimicrobial | 10.1 ± 9.9 | 6.1 ± 3.5 | *N.S. |
ESBL (+): patients infected with ESBL-producing E. coli; ESBL (–): patients not infected with ESBL-producing E. coli; N.S.: not significant. All statistical tests were performed using Fisher’s exact test except for data indicated by *, for which Mann-Whitney U-test was used.